KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Gross Profit: 2009-2025

Historic Gross Profit for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $997.2 million.

  • Jazz Pharmaceuticals' Gross Profit rose 5.71% to $997.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 3.50%. This contributed to the annual value of $3.6 billion for FY2024, which is 6.61% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Gross Profit of $997.2 million as of Q3 2025, which was up 25.72% from $793.2 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Gross Profit peaked at $997.2 million during Q3 2025, and registered a low of $567.4 million during Q1 2021.
  • In the last 3 years, Jazz Pharmaceuticals' Gross Profit had a median value of $887.3 million in 2023 and averaged $881.2 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Gross Profit increased by 27.83% in 2022, and later declined by 13.21% in 2025.
  • Jazz Pharmaceuticals' Gross Profit (Quarterly) stood at $760.6 million in 2021, then increased by 5.81% to $804.8 million in 2022, then rose by 12.42% to $904.7 million in 2023, then increased by 6.05% to $959.5 million in 2024, then grew by 5.71% to $997.2 million in 2025.
  • Its last three reported values are $997.2 million in Q3 2025, $793.2 million for Q2 2025, and $959.5 million during Q4 2024.